Skip to main content

Advertisement

Table 1 Patients characteristics

From: Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -

Variables Naftopidil (n=70) Silodosin (n=71) p-value
Age median (range) 72 (56–83) 70 (57–83) 0.216*
PSA (ng/mL) median range 6.5 (3.7-31.8) 7.2 (3.5-17.7) 0.421*
Duration of NeoADT (month) median (range) 4 (2–43) 4 (1–34) 0.640*
Prostate volume (mL) at impant median (range) 26 (8–42) 27 (10–48) 0.187*
IPSS at baseline median (range) 6 (0–17) 7 (0–23) 0.132*
OABSS at baseline median (range) 3 (0–8) 3 (0–10) 0.343*
No of needle/seeds median (range) 22 (15–30)/60 (40–90) 22 (16–30)/65 (35–90) 0.304/0.128*
Total activity (MBq) median (range) 875 (449–1314) 876 (438–1314) 0.221*
Stage T1c/T2a/T2b/T2c/T3a 38/25/6/1/0 37/28/4/1/1 0.813
Gleason score −6/7/8-10 44/24/2 45/24/2 0.648
Neoadjuvant ADT yes/no 20/50 21/50 1.000
EBRT yes/no 17/53 17/54 1.000
Pre use of alpha-1 antagonist yes/no 12/58 10/61 0.649
  1. Neo ADT: neoadjuvant androgen deprivation theraphy.
  2. *Mann–Whitney U test.
  3. EBRT: external beam radiation therapy.
  4. chi-square test.